DOCSLIB.ORG

Ep 2811298 A1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

(19) TZZ __ _T (11) EP 2 811 298 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 10.12.2014 Bulletin 2014/50 G01N 33/53 (2006.01) G01N 33/542 (2006.01) (21) Application number: 13002949.9 (22) Date of filing: 07.06.2013 (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • Hall, Jonathan GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO 4143 Dornach (CH) PL PT RO RS SE SI SK SM TR • Pradere, Ugo Designated Extension States: 8046 Zürich (CH) BA ME •Roos,Martina 8050 Zürich (CH) (71) Applicant: ETH Zurich 8092 Zurich (CH) (54) FRET-Method for identifying a biomolecule-modulating compound (57) The present invention relates to a method for the excitation energy spectrum of the fluorophore accep- identifying a compound modulating an interaction be- tor or the energy spectrum absorbed by the dark quench- tween two biomolecules or two domains of one biomol- er overlap at least partially. Preferably, the first and sec- ecule, the first biomolecule or first domain comprising at ond biomolecules are selected from the group consisting least one fluorophore donor and the second biomolecule of polypeptides, sugars, polynucleotides, polyamines or second domain comprising at least one fluorophore and lipids, and more preferably the first biomolecule is acceptor or a dark quencher, wherein the fluorophore selected from the group consisting of polypeptides inter- donor and fluorophore acceptor or the fluorophore donor acting with polynucleotides and the second biomolecule and dark quencher are spectrally paired such that the is selected from the group consisting of polynucleotides, energy spectrum emitted by.the fluorophore donor and preferably microRNAs (miRNA). EP 2 811 298 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 811 298 A1 Description [0001] The present invention relates to a method for identifying a compound modulating an interaction between two biomolecules or two domains of one biomolecule, the first biomolecule or first domain comprising at least one fluorophore 5 donor and the second biomolecule or second domain comprising at least one fluorophore acceptor or a dark quencher, wherein the fluorophore donor and fluorophore acceptor or the fluorophore donor and dark quencher are spectrally paired such that the energy spectrum emitted by the fluorophore donor and the excitation energy spectrum of the fluorophore acceptor or the energy spectrum absorbed by the dark quencher overlap at least partially. Preferably, the first and second biomolecules are selected from the group consisting of polypeptides, sugars, polynucleotides, 10 polyamines and lipids, and more preferably the first biomolecule is selected from the group consisting of polypeptides interacting with polynucleotides and the second biomolecule is selected from the group consisting of polynucleotides, preferably4 microRNAs (miRNA). Background of the invention 15 [0002] The field of the invention relates to the use of Förster resonance energy transfer (FRET), which is a mechanism describing energy transfer between two chromophores. When both chromophores are fluorescent, i.e. so-called fluor- ophores, the term "fluorescence resonance energy transfer" is often used instead. In order to avoid an erroneous interpretation of the phenomenon that is always a non-radiative transfer of energy (even when occurring between two 20 fluorophores), the name "Förster resonance energy transfer" is preferred. A fluorophore donor, initially in its electronically excited state, may transfer energy to a fluorophore acceptor through non-radiative dipole-dipole coupling. The efficiency of this energy transfer is inversely proportional to the sixth power of the distance between donor and acceptor making FRET extremely sensitive to small distances. [0003] Measurements of FRET efficiency can be used to determine if two fluorophores are within a certain distance 25 of each other, typically in the proximity of 1 to 10 nm. Such measurements are used as research tools in biology and chemistry. FRET is typically determined by measuring the variation in acceptor emission intensity. When the donor and acceptor are in proximity the acceptor emission will increase because of the FRET from the donor to the acceptor (sensitized emission). FRET efficiencies can also be inferred from the photobleaching rates of the donor in the-presence and absence of an acceptor. 30 [0004] Alternatively, FRET can be measured between a fluorophore donor and a dark quencher. A dark quencher is a family of substances that absorbs emission energy from a fluorophore donor and dissipates the energy as non-UV- visible light or heat, whereas a typical "fluorescent quencher" i.e. fluorophore acceptor re-emits much of the "donated" energy as light. Black hole quencher (BHQ™) dyes from Biosearch Technologies, Inc., Novato, California. USA) are examples of members of the dark quencher family. Dark quenchers such as BHQ dyes are used in molecular biology 35 in conjunction with fluorophores. When the two are close together, e.g. 10-100 A, such as in a molecule, e.g. a protein, the donor’s emission is at least partially suppressed by the quencher. This effect can be used to study molecular geometry and motion. [0005] MicroRNAs (miRNA) are a large class of small non-coding RNAs which modulate protein translation as negative gene regulators by post-transcriptionally repressing gene expression. They are involved in cell differentiation, develop- 40 ment and metabolism. MiRNAs can function as tumor suppressors and oncogenes. The dysregulation of miRNA ex- pression has been linked to various human malignancies, in particular human cancers, and therefore miRNAs represent a new class of potential drug targets. Mature miRNAs are produced from long primary miRNA transcripts (pri-miRNAs) through sequential cleavages by the Micro-processor and Dicer complexes to release pre-miRNA and mature miRNA species, respectively. MiRNAs regulate the expression of a large part of the human genome by binding to partially 45 complementary sites in the 3’ UTRs of mRNAs and inhibiting protein translation or inducing deadenylation and degra- dation. [0006] Lin28, also called Lin28a and its homologue Lin28b are one of many thousands of RNA binding proteins (RBPs, see list in appended Table 1) which bind to a specific motif (GGAG, or GNNG where N is any ribonucleotide) in pri- and pre-let-7 miRNAs inhibiting their processing and depleting cells of mature let-7. This mechanism appears to be quite 50 general and occurs in about 15% of tumors of different histology and Lin28 and Lin28b activation is associated with advanced disease and poor clinical prognosis (see e.g. Viswanathan, et al., Nat Gen, 2009, 41, 843). [0007] Roos et al. (Poster by ETH Zürich, Institute of Pharmaceutical Sciences, Department of Applied Sciences: "Antisense oligonucleotides inhibit LIN28 binding to pre-let-7" Keystone Conference, "Noncoding RNAs in Development and Cancer", January 20-25, 2013, Vancouver, Canada) designed and tested methoxy antisense oligonucleotides (ASO) 55 to specifically antagonize Lin28 from binding to the terminal loop region of pre-let-7 in order to elevate processing by Dicer and Drosha in order to prevent the cell from mature let-7 loss. These ASOs were tested by an RNA-based competition ELISA. Kd-values of a selection of tested ASO were determined by Surface Plasmon Resonance (SPR) measurements. The two best ASOs were tested in a biochemical Dicer assay using HPCL-MS for analysis to ensure a 2 EP 2 811 298 A1 proper pre-let-7a-2 processing by Dicer in presence of ASO. [0008] Yeom et al. (EMBO REPORTS, 12:7, 690-696, 2011) teaches a method for integrating single-molecule fluo- rescence microscopy and immunopurification.to investigate Lin28-mediated microRNA uridylation by TUT4 (terminal uridylyl transferase 4, polyU polymerase), which also regulates let-7 microRNA biogenesis. TUT4 immunoprecipitates 5 together with fluorescent Cy5-labelled miRNA pre-let-7. The real-time analysis of the uridylation by the TUT4 immuno- precipitates suggests that Lin28 functions as a processivity factor of TUT4 in the Lin28/TUT4/let-7 complex. [0009] WO 2009/048935 A2 discloses a method for promoting miRNA processing of pri-let-7 miRNA to mature miRNA in a human cancer cell, the method comprising contacting a cell with an agent inhibiting the activity or expression of Lin-28. [0010] It is the objective of the present invention to provide an improved and high throughput screening (HTS)-suitabie- 10 assay for identifying a compound modulating an interaction between two biomolecules such as e.g. polypeptides, sugars, polynucleotides, polyamines and lipids or between two domains of the same biomolecule. In particular it is an objective of the present invention to provide an improved HTS-suitable assay for identifying a compound modulating an interaction between polypeptides and polynucleotides, preferably microRNAs(miRNA). [0011] This objective is solved according to the present invention by a method for identifying a compound modulating 15 an interaction between two biomolecules or two domains of one biomolecule, the first biomolecule or first domain com- prising at least one fluorophore donor and the second biomolecule or second domain comprising at least one fluorophore acceptor or a dark quencher, wherein the fluorophore donor and fluorophore acceptor or the fluorophore donor and dark quencher are spectrally paired such that the energy spectrum emitted by the fluorophore donor and the excitation energy spectrum of the fluorophore
Recommended publications
  • A 475 Years-Old Founder Effect Involving IL12RB1: a Highly Prevalent Mutation Conferring Mendelian Susceptibility to Mycobacterial Diseases in European Descendants

    A 475 Years-Old Founder Effect Involving IL12RB1: a Highly Prevalent Mutation Conferring Mendelian Susceptibility to Mycobacterial Diseases in European Descendants

    Infection, Genetics and Evolution 9 (2009) 574–580 Contents lists available at ScienceDirect Infection, Genetics and Evolution journal homepage: www.elsevier.com/locate/meegid A 475 years-old founder effect involving IL12RB1: A highly prevalent mutation conferring Mendelian Susceptibility to Mycobacterial Diseases in European descendants J. Yancoski a, C. Rocco a, A. Bernasconi a, M. Oleastro a, L. Bezrodnik b, C. Vra´tnica c, F. Haerynck d, S.D. Rosenzweig a,* a Hospital Nacional de Pediatrı´a J. P. Garrahan, Buenos Aires, Argentina b Hospital de Nin˜os Ricardo Gutierrez, Buenos Aires, Argentina c Hospital de Nin˜os Juan Pablo II, Corrientes, Argentina d Ghent University Hospital, Ghent, Belgium ARTICLE INFO ABSTRACT Article history: Mutations in IFNGR1, IFNGR2, IL12RB1, IL12B, STAT1 and NEMO result in a common clinical phenotype Received 11 December 2008 known as Mendelian Susceptibility to Mycobacterial Diseases (MSMD). Interleukin-12 receptor b1 (IL- Received in revised form 13 February 2009 12Rb1) deficiency is the most common genetic etiology for MSMD. Known mutations affecting IL12RB1 Accepted 16 February 2009 are recessively inherited and are associated with null response to both IL-12 and IL-23. Mutation IL12RB1 Available online 9 March 2009 1623_1624delinsTT was originally described in 5 families from European origin (2 from Germany; 1 from Cyprus, France and Belgium). Interestingly, this same mutation was found in an unexpectedly high Keywords: prevalence among IL-12Rb1 deficient patients in Argentina: 5-out-of-6 individuals born to unrelated Hot spot families carried this particular change. To determine whether mutation 1623_1624delinsTT represents a Salmonella Bacillus Calmette Guerin DNA mutational hotspot or a founder effect, 34 polymorphic markers internal or proximal to IL12RB1 Interferon gamma were studied in the Argentinean and the Belgian patients.
  • NIH Public Access Author Manuscript Gene

    NIH Public Access Author Manuscript Gene

    NIH Public Access Author Manuscript Gene. Author manuscript; available in PMC 2010 June 21. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Gene. 2007 July 15; 396(2): 373±390. doi:10.1016/j.gene.2007.04.021. Formation of the 3’ end of histone mRNA: Getting closer to the end Zbigniew Dominski* and William F. Marzluff Department of Biochemistry and Biophysics and Program in Molecular Biology and Biotechnology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA Abstract Nearly all eukaryotic mRNAs end with a poly (A) tail that is added to their 3’ end by the ubiquitous cleavage/polyadenylation machinery. The only known exception to this rule are metazoan replication dependent histone mRNAs, which end with a highly conserved stem-loop structure. This distinct 3’ end is generated by specialized 3’end processing machinery that cleaves histone pre-mRNAs 4–5 nucleotides downstream of the stem-loop and consists of the U7 small nuclear RNP (snRNP) and number of protein factors. Recently, the U7 snRNP has been shown to contain a unique Sm core that differs from that of the spliceosomal snRNPs, and an essential heat labile processing factor has been identified as symplekin. In addition, cross-linking studies have pinpointed CPSF-73 as the endonuclease, which catalyzes the cleavage reaction. Thus, many of the critical components of the 3’ end processing machinery are now identified. Strikingly, this machinery is not as unique as initially thought but contains a number of factors involved in cleavage/polyadenylation, suggesting that the two mechanisms have a common evolutionary origin.
  • SFRS14 Antibody (Monoclonal) (M01) Mouse Monoclonal Antibody Raised Against a Partial Recombinant SFRS14

    SFRS14 Antibody (Monoclonal) (M01) Mouse Monoclonal Antibody Raised Against a Partial Recombinant SFRS14

    苏州工业园区双圩路9号1幢 邮 编 ： 215000 电 话 ： 0512-88856768 SFRS14 Antibody (monoclonal) (M01) Mouse monoclonal antibody raised against a partial recombinant SFRS14. Catalog # AT3845a Specification SFRS14 Antibody (monoclonal) (M01) - Product info Application WB, IHC, IF, E Primary Accession Q8IX01 Other Accession NM_014884 Reactivity Human Host mouse Clonality monoclonal Isotype IgG2a Kappa Clone Names 3C5 Calculated MW 120207 SFRS14 Antibody (monoclonal) (M01) - Additional info Gene ID 10147 Antibody Reactive Against Recombinant Protein.Western Blot detection against Other Names Immunogen (36.3 KDa) . SURP and G-patch domain-containing protein 2, Arginine/serine-rich-splicing factor 14, Splicing factor, arginine/serine-rich 14, SUGP2, KIAA0365, SFRS14 Target/Specificity SFRS14 (NP_055699, 579 a.a. ~ 674 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. Dilution WB~~1:500~1000 Format Clear, colorless solution in phosphate buffered saline, pH 7.2 . Storage Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. SFRS14 monoclonal antibody (M01), Precautions clone 3C5 Western Blot analysis of SFRS14 Antibody (monoclonal) (M01) is for research use only SFRS14 expression in Hela S3 NE ( (Cat # and not for use in diagnostic or therapeutic procedures. AT3845a ) SFRS14 Antibody (monoclonal) (M01) - Protocols Provided below are standard protocols that you may find useful for product applications. • Western Blot • Blocking Peptides • Dot Blot • Immunohistochemistry • Immunofluorescence • Immunoprecipitation Immunoperoxidase of monoclonal • Flow Cytomety antibody to SFRS14 on formalin-fixed • Cell Culture paraffin-embedded human testis. SFRS14 Antibody (monoclonal) (M01) - Background [antibody concentration 3 ug/ml] This gene encodes a member of the arginine/serine-rich family of splicing factors.
  • Nutrigenomics in Human Peripheral Blood Mononuclear Cells

    Nutrigenomics in Human Peripheral Blood Mononuclear Cells

    Nutrigenomics in human peripheral blood mononuclear cells The effects of fatty acids on gene expression profiles of human circulating cells as assessed in human intervention studies Mark Bouwens Promotor Prof. dr. Michael R. Müller Hoogleraar Voeding, Metabolisme en Genomics Afdeling Humane Voeding, Wageningen Universiteit Co-promotor Dr. ir. Lydia A. Afman Universitair docent Afdeling Humane Voeding, Wageningen Universiteit Promotiecommissie Prof. dr. Hannelore Daniel Technical University of Munich, Germany Dr. ir. Baukje de Roos Rowett Research Institute, Scotland Prof. dr. ir. Wim H.M. Saris Universiteit Maastricht Prof. dr. Huub F.J. Savelkoul Wageningen Universiteit Dit onderzoek is uitgevoerd binnen de onderzoeksschool VLAG (Voeding, Levensmiddelentechnologie, Agrobiotechnologie en Gezondheid) Nutrigenomics in human peripheral blood mononuclear cells The effects of fatty acids on gene expression profiles of human circulating cells as assessed in human intervention studies Mark Bouwens Proefschrift ter verkrijging van de graad van doctor op gezag van de rector magnificus van Wageningen Universiteit, Prof. dr. M.J. Kropff, in het openbaar te verdedigen op vrijdag 20 februari 2009 des namiddags te half twee in de Aula. Mark Bouwens Nutrigenomics in human peripheral blood mononuclear cells. The effects of fatty acids on gene expression profiles of human circulating cells as assessed in human intervention studies Thesis Wageningen University, Wageningen, the Netherlands, 2009. With abstract – with references – with summary in Dutch. ISBN: 978-90-8585-327-5 Abstract Nutrigenomics in human peripheral blood mononuclear cells. The effects of fatty acids on gene expression profiles of human circulating cells as assessed in human intervention studies PhD thesis by Mark Bouwens, Division of Human Nutrition, Wageningen University, Wageningen, the Netherlands, February 20, 2009 Peripheral blood mononuclear cells (PBMCs) are circulating immune cells.
  • WO 2010/129023 A9 11 November 2010 (11.11.2010) PCT

    WO 2010/129023 A9 11 November 2010 (11.11.2010) PCT

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) CORRECTED VERSION (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2010/129023 A9 11 November 2010 (11.11.2010) PCT (51) International Patent Classification: (74) Agent: BAKER, C , Hunter; Wolf, Greenfield & Sacks, C07K 14/00 (2006.01) P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US). (21) International Application Number: PCT/US20 10/00 1250 (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, 28 April 2010 (28.04.2010) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (26) Publication Langi English KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (30) Priority Data: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 61/173,430 28 April 2009 (28.04.2009) US NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, 61/321,428 6 April 2010 (06.04.2010) US SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant (for all designated States except US): PRESI¬ DENT AND FELLOWS OF HARVARD COLLEGE (84) Designated States (unless otherwise indicated, for every [US/US]; 17 Quincy Street, Cambridge, MA 02138 (US).
  • Rabbit Anti-DAZAP1/FITC Conjugated Antibody-SL14200R-FITC

    Rabbit Anti-DAZAP1/FITC Conjugated Antibody-SL14200R-FITC

    SunLong Biotech Co.,LTD Tel: 0086-571- 56623320 Fax:0086-571- 56623318 E-mail:[email protected] www.sunlongbiotech.com Rabbit Anti-DAZAP1/FITC Conjugated antibody SL14200R-FITC Product Name: Anti-DAZAP1/FITC Chinese Name: FITC标记的无精症缺失相关蛋白1抗体 DAZ associated protein 1; DAZ-associated protein 1; Dazap1; DAZP1_HUMAN; Alias: Deleted in azoospermia associated protein 1; Deleted in azoospermia-associated protein 1. Organism Species: Rabbit Clonality: Polyclonal React Species: Human,Mouse,Rat,Chicken,Dog,Pig,Cow,Horse,Sheep, ICC=1:50-200IF=1:50-200 Applications: not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. Molecular weight: 43kDa Form: Lyophilized or Liquid Concentration: 1mg/ml immunogen: KLH conjugated synthetic peptide derived from human DAZAP1 Lsotype: IgG Purification: affinity purified by Protein A Storage Buffer: 0.01Mwww.sunlongbiotech.com TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year Storage: when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. background: In mammals, the Y chromosome directs the development of the testes and plays an important role in spermatogenesis. A high percentage of infertile men have deletions that map to regions of the Y chromosome. The DAZ (deleted in azoospermia) gene Product Detail: cluster maps to the AZFc region of the Y chromosome and is deleted in many azoospermic and severely oligospermic men.
  • The Role of Nuclear Bodies in Gene Expression and Disease

    The Role of Nuclear Bodies in Gene Expression and Disease

    Biology 2013, 2, 976-1033; doi:10.3390/biology2030976 OPEN ACCESS biology ISSN 2079-7737 www.mdpi.com/journal/biology Review The Role of Nuclear Bodies in Gene Expression and Disease Marie Morimoto and Cornelius F. Boerkoel * Department of Medical Genetics, Child & Family Research Institute, University of British Columbia, Vancouver, BC V5Z 4H4, Canada; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-604-875-2157; Fax: +1-604-875-2376. Received: 15 May 2013; in revised form: 13 June 2013 / Accepted: 20 June 2013 / Published: 9 July 2013 Abstract: This review summarizes the current understanding of the role of nuclear bodies in regulating gene expression. The compartmentalization of cellular processes, such as ribosome biogenesis, RNA processing, cellular response to stress, transcription, modification and assembly of spliceosomal snRNPs, histone gene synthesis and nuclear RNA retention, has significant implications for gene regulation. These functional nuclear domains include the nucleolus, nuclear speckle, nuclear stress body, transcription factory, Cajal body, Gemini of Cajal body, histone locus body and paraspeckle. We herein review the roles of nuclear bodies in regulating gene expression and their relation to human health and disease. Keywords: nuclear bodies; transcription; gene expression; genome organization 1. Introduction Gene expression is a multistep process that is vital for the development, adaptation and survival of all living organisms. Regulation of gene expression occurs at the level of transcription, RNA processing, RNA export, translation and protein degradation [1±3]. The nucleus has the ability to modulate gene expression at each of these levels. How the nucleus executes this regulation is gradually being dissected.
  • Purified U7 Snrnps Lack the Sm Proteins D1 and D2 but Contain

    Purified U7 Snrnps Lack the Sm Proteins D1 and D2 but Contain

    The EMBO Journal Vol. 20 No. 19 pp. 5470±5479, 2001 Puri®ed U7 snRNPs lack the Sm proteins D1 and D2 but contain Lsm10, a new 14 kDa Sm D1-like protein Ramesh S.Pillai1, Cindy L.Will2, The U11 and U12 snRNPs contain the common Sm Reinhard LuÈ hrmann2, Daniel SchuÈ mperli1,3 proteins, interacting with canonical Sm binding sites, and Berndt MuÈ ller1,4 certain U2 snRNP-speci®c proteins also present in the U12 snRNP, and new kinds of U11 and U12 snRNP-speci®c 1 Institute of Cell Biology, University of Bern, Baltzerstrasse 4, 3012 proteins that may be functional equivalents of U1- and U2- Bern, Switzerland, 2Max Planck Institute of Biophysical Chemistry, Am Fassberg 11, 37070 GoÈttingen, Germany and 4Department of speci®c proteins (Will et al., 1999). Molecular and Cell Biology, Institute of Medical Sciences, University Another minor snRNP, the U7 snRNP, is an essential of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK cofactor for 3¢-end processing of the replication-dependent 3Corresponding author histone pre-mRNAs in metazoans (reviewed in MuÈller and e-mail: [email protected] SchuÈmperli, 1997; Dominski and Marzluff, 1999). These histone transcripts lack introns and a poly(A) tail in the U7 snRNPs were isolated from HeLa cells by biochem- mature message. The endonucleolytic cleavage generating ical fractionation, followed by af®nity puri®cation the mRNA 3¢-end is distinct from the cleavage-poly- with a biotinylated oligonucleotide complementary to adenylation reaction that processes all other mRNAs. The U7 snRNA. Puri®ed U7 snRNPs lack the Sm proteins U7 snRNA is 58±63 nucleotides (nt) long, depending on D1 and D2, but contain additional polypeptides of 14, the species.
  • 1 Mutational Heterogeneity in Cancer Akash Kumar a Dissertation

    1 Mutational Heterogeneity in Cancer Akash Kumar a Dissertation

    Mutational Heterogeneity in Cancer Akash Kumar A dissertation Submitted in partial fulfillment of requirements for the degree of Doctor of Philosophy University of Washington 2014 June 5 Reading Committee: Jay Shendure Pete Nelson Mary Claire King Program Authorized to Offer Degree: Genome Sciences 1 University of Washington ABSTRACT Mutational Heterogeneity in Cancer Akash Kumar Chair of the Supervisory Committee: Associate Professor Jay Shendure Department of Genome Sciences Somatic mutation plays a key role in the formation and progression of cancer. Differences in mutation patterns likely explain much of the heterogeneity seen in prognosis and treatment response among patients. Recent advances in massively parallel sequencing have greatly expanded our capability to investigate somatic mutation. Genomic profiling of tumor biopsies could guide the administration of targeted therapeutics on the basis of the tumor’s collection of mutations. Central to the success of this approach is the general applicability of targeted therapies to a patient’s entire tumor burden. This requires a better understanding of the genomic heterogeneity present both within individual tumors (intratumoral) and amongst tumors from the same patient (intrapatient). My dissertation is broadly organized around investigating mutational heterogeneity in cancer. Three projects are discussed in detail: analysis of (1) interpatient and (2) intrapatient heterogeneity in men with disseminated prostate cancer, and (3) investigation of regional intratumoral heterogeneity in
  • Coding RNA Genes

    Coding RNA Genes

    Review A guide to naming human non-coding RNA genes Ruth L Seal1,2,* , Ling-Ling Chen3, Sam Griffiths-Jones4, Todd M Lowe5, Michael B Mathews6, Dawn O’Reilly7, Andrew J Pierce8, Peter F Stadler9,10,11,12,13, Igor Ulitsky14 , Sandra L Wolin15 & Elspeth A Bruford1,2 Abstract working on non-coding RNA (ncRNA) nomenclature in the mid- 1980s with the approval of initial gene symbols for mitochondrial Research on non-coding RNA (ncRNA) is a rapidly expanding field. transfer RNA (tRNA) genes. Since then, we have worked closely Providing an official gene symbol and name to ncRNA genes brings with experts in the ncRNA field to develop symbols for many dif- order to otherwise potential chaos as it allows unambiguous ferent kinds of ncRNA genes. communication about each gene. The HUGO Gene Nomenclature The number of genes that the HGNC has named per ncRNA class Committee (HGNC, www.genenames.org) is the only group with is shown in Fig 1, and ranges in number from over 4,500 long the authority to approve symbols for human genes. The HGNC ncRNA (lncRNA) genes and over 1,900 microRNA genes, to just four works with specialist advisors for different classes of ncRNA to genes in the vault and Y RNA classes. Every gene symbol has a ensure that ncRNA nomenclature is accurate and informative, Symbol Report on our website, www.genenames.org, which where possible. Here, we review each major class of ncRNA that is displays the gene symbol, gene name, chromosomal location and currently annotated in the human genome and describe how each also includes links to key resources such as Ensembl (Zerbino et al, class is assigned a standardised nomenclature.
  • Rashid Thesis 2015

    Rashid Thesis 2015

    Protein Profile and Directed Gene Expression of Developing C2C12 cells By Susan Rashid Submitted in Partial Fulfillment of the Requirements For the Degree of Master of Science In the Biological Sciences Program YOUNGSTOWN STATE UNIVERSITY August 3, 2015 Protein Profile and Directed Gene Expression of Developing C2C12 cells Susan Rashid I hereby release this thesis to the public. I understand that this will be made available from the OhioLINK ETD Center and the Maag Library Circulation Desk for public access. I also authorize the University or other individuals to make copies of this thesis as needed for scholarly research. Signature: ___________________________________________________ Susan Rashid, Student Date Approvals: ___________________________________________________ Dr. Gary Walker, Thesis Advisor 'ate ___________________________________________________ Dr. Jonathan Caguiat, Committee Member Date ___________________________________________________ Dr. David Asch, Committee Member Date ___________________________________________________ Dr. Sal Sanders, Associate Dean, Graduate Studies Date ABSTRACT Myogenesis is a tightly regulated process resulting in unique structures called myotubes or myofibers, which compose skeletal muscle. Myotubes are multi-nucleated fibers containing a functional unit composed of cytoskeletal proteins called the sarcomere. The specific arrangement of these proteins in the sarcomere works to contract and relax muscles. During embryonic and post-embryonic development, fluctuations in expression of growth factors throughout the program account for the dramatic structural changes from cell to mature muscle fiber. In vivo, these growth factors are strictly spatiotemporally regulated according to a ‘myogenic program.’ In order to assess the dynamics of protein expression throughout this program, we conducted a time course study using the mouse myoblast cell line C2C12, in which cells were allowed to differentiate and insoluble protein fractions were collected at seven time points.
  • Genome Wide Association Study of Hippocampal Subfield Volume in PTSD Cases and Trauma-Exposed Controls

    Genome Wide Association Study of Hippocampal Subfield Volume in PTSD Cases and Trauma-Exposed Controls

    bioRxiv preprint doi: https://doi.org/10.1101/456988; this version posted October 30, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Hippocampal subfield GWAS in PTSD Revision date: October 18, 2018 Genome wide association study of hippocampal subfield volume in PTSD cases and trauma-exposed controls Rajendra A. Morey, M.D., M.S. a, b, c, Melanie E. Garrett, M.S. a, d, Jennifer S. Stevens, Ph.D. e, Emily Clarke, M.A. a, c, Courtney C. Haswell, M.S. a, c, Sanne J.H. van Rooij, Ph.D. e, Negar Fani, Ph.D. e, Adriana Lori, Ph.D. e, VA Mid-Atlantic MIRECC Workgroup†, Christine E. Marx, M.D. a, b, Jean C. Beckham, Ph.D. a, Gregory McCarthy, Ph.D. f, Michael A. Hauser, Ph.D. a, d, Allison E. Ashley-Koch, Ph.D. a, d †The VA Mid-Atlantic MIRECC Workgroup includes the following contributors: Mira Brancu, Ph.D., Patrick S. Calhoun, Ph.D., Eric Dedert, Ph.D., Eric B. Elbogen, Ph.D., John A. Fairbank, Ph.D., Robin A. Hurley, M.D., Jason D. Kilts, Ph.D., Nathan Kimbrel, Ph.D., Angela Kirby, M.S., Scott D. McDonald, Ph.D., Ph.D., Scott D. Moore, M.D., Ph.D., Jennifer C. Naylor, Ph.D., Jared Rowland, Ph.D., Cindy Swinkels, Ph.D., Steven T. Szabo, M.D., Ph.D., Katherine H. Taber, Ph.D., Larry A. Tupler, Ph.D., Elizabeth E. Van Voorhees, Ph.D., H.